Malditesta

Paracetamol and Metoclopramide Hydrochloride Monohydrate, the active ingredients in Malditesta, are an analgesic and antiemetic combination presented as an oral tablet for oral use. The product is indicated for relief of mild to moderate pain, fever, and for prevention or treatment of nausea and vomiting in postoperative or chemotherapy settings. GNH USA supplies Malditesta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malditesta acts on pain pathways and the central chemoreceptor trigger zone to provide relief in several clinical situations. - Mild to moderate pain and fever: provides analgesic and antipyretic relief. - Postoperative nausea and vomiting: prevents and treats nausea after surgery. - Chemotherapy‑induced nausea and vomiting: reduces nausea associated with cancer treatment.

Adverse reactions may occur with Malditesta and should be monitored.

Common Side Effects: - Drowsiness: mild sedation or sleepiness. - Dizziness: sensation of light‑headedness. - Headache: transient cranial pain. - Dry mouth: reduced salivation. - Constipation: slowed bowel movements.

Serious or Rare Side Effects: - Extrapyramidal symptoms: involuntary muscle movements or rigidity. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Malditesta, consider the following precautions. - Pregnancy: consult a healthcare provider before use. - Breastfeeding: assess risk versus benefit for the infant. - Elderly patients: monitor for increased sedation and extrapyramidal effects. - Renal or hepatic impairment: dose adjustment may be required. - Concomitant CNS depressants: may enhance sedative effects. - Store at ambient temperature: keep in the original container, protect from moisture.

Malditesta may interact with other medicines; awareness of major and moderate interactions is important.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): increased risk of extrapyramidal reactions. - MAO inhibitors: potential hypertensive crisis when combined with metoclopramide. - CYP450 inducers (e.g., rifampicin): may reduce paracetamol efficacy.

Moderate Interactions (Monitor Closely): - Opioids: additive central nervous system depression. - Anticholinergics: may diminish metoclopramide’s pro‑kinetic effect. - Warfarin: paracetamol can enhance anticoagulant activity, requiring INR monitoring.